Mechanisms of multidrug resistance and implications for therapy.
作者信息
Tsuruo T
机构信息
Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo.
出版信息
Jpn J Cancer Res. 1988 Mar;79(3):285-96. doi: 10.1111/j.1349-7006.1988.tb01588.x.
Abstract
摘要
相似文献
1
Mechanisms of multidrug resistance and implications for therapy.多药耐药机制及其对治疗的影响。
Jpn J Cancer Res. 1988 Mar;79(3):285-96. doi: 10.1111/j.1349-7006.1988.tb01588.x.
2
[Multidrug resistance of malignant tumors].[恶性肿瘤的多药耐药性]
Orv Hetil. 1991 Oct 6;132(40):2187-92.
3
Multidrug resistance: mechanism and therapy.多药耐药性：机制与治疗
Jpn J Cancer Res. 1993 Dec;84(12):inside front cover.
4
The multidrug resistance phenotype.多药耐药表型
Br J Cancer. 1988 Dec;58(6):691-4. doi: 10.1038/bjc.1988.291.
5
Multidrug resistance in the laboratory and clinic.
Cancer Cells. 1989 Sep;1(1):33-6.
6
Multidrug resistance in cancer.癌症中的多药耐药性。
Lancet. 1989 Nov 4;2(8671):1075-6.
7
[Modulators of multidrug resistance in neoplastic cells].[肿瘤细胞中多药耐药的调节剂]
Postepy Biochem. 1989;35(4):543-61.
8
[The individualized therapy of tumors].[肿瘤的个体化治疗]
Dtsch Med Wochenschr. 1992 Oct 30;117(44):1685-9. doi: 10.1055/s-2008-1062499.
9
Human ABC transporter ABCG2 in cancer chemotherapy: drug molecular design to circumvent multidrug resistance.人类ABC转运蛋白ABCG2在癌症化疗中的作用：规避多药耐药性的药物分子设计
Methods Mol Biol. 2012;910:267-78. doi: 10.1007/978-1-61779-965-5_11.
10
High-dose combination chemotherapy: why, how, and when.
Mt Sinai J Med. 1985 Jun;52(6):447-51.
引用本文的文献
1
Predicting Anticancer Drug Resistance Mediated by Mutations.预测由突变介导的抗癌药物耐药性。
Pharmaceuticals (Basel). 2022 Jan 24;15(2):136. doi: 10.3390/ph15020136.
2
CD56 and CD11b Positivity with Low Smac/DIABLO Expression as Predictors of Chemoresistance in Acute Myeloid Leukaemia: Flow Cytometric Analysis.CD56和CD11b阳性伴低Smac/DIABLO表达作为急性髓系白血病化疗耐药的预测指标：流式细胞术分析
Asian Pac J Cancer Prev. 2018 Nov 29;19(11):3187-3192. doi: 10.31557/APJCP.2018.19.11.3187.
3
Hard clam extracts induce atypical apoptosis in human gastric cancer cells.硬壳蛤提取物诱导人胃癌细胞发生非典型凋亡。
Exp Ther Med. 2017 Aug;14(2):1409-1418. doi: 10.3892/etm.2017.4630. Epub 2017 Jun 20.
4
Apoptosis resistance in tumor cells.肿瘤细胞的凋亡抵抗。
Cytotechnology. 1998 Sep;27(1-3):293-308. doi: 10.1023/A:1008058031511.
5
Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia.多药耐药1（MDR1）、多药耐药相关蛋白1（MRP1）、肺耐药蛋白（LRP）和乳腺癌耐药蛋白（BCRP）基因的表达与儿童急性淋巴细胞白血病的临床结局
Int J Hematol. 2007 Aug;86(2):166-73. doi: 10.1532/IJH97.E0624.
6
Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal.癌症的分子靶向治疗：耐药性、细胞凋亡与生存信号
Cancer Sci. 2003 Jan;94(1):15-21. doi: 10.1111/j.1349-7006.2003.tb01345.x.
7
Reversal of multidrug resistance by novel nitrophenyl pyrones, SNF4435C and D.新型硝基苯基吡喃酮SNF4435C和D逆转多药耐药性
Jpn J Cancer Res. 2001 Nov;92(11):1235-41. doi: 10.1111/j.1349-7006.2001.tb02145.x.
8
A new quinoline derivative MS-209 reverses multidrug resistance and inhibits multiorgan metastases by P-glycoprotein-expressing human small cell lung cancer cells.一种新型喹啉衍生物MS-209可逆转多药耐药性，并抑制表达P-糖蛋白的人小细胞肺癌细胞的多器官转移。
Jpn J Cancer Res. 2001 Jul;92(7):785-92. doi: 10.1111/j.1349-7006.2001.tb01162.x.
9
Multidrug resistance reversal activity of taxoids from Taxus cuspidata in KB-C2 and 2780AD cells.东北红豆杉中紫杉烷类化合物对KB-C2和2780AD细胞的多药耐药逆转活性
Jpn J Cancer Res. 2000 Jun;91(6):638-42. doi: 10.1111/j.1349-7006.2000.tb00993.x.
10
Uptake and intracellular distribution of amrubicin, a novel 9-amino-anthracycline, and its active metabolite amrubicinol in P388 murine leukemia cells.新型9-氨基蒽环类药物氨柔比星及其活性代谢产物氨柔比星醇在P388小鼠白血病细胞中的摄取及细胞内分布
Jpn J Cancer Res. 1999 Jun;90(6):685-90. doi: 10.1111/j.1349-7006.1999.tb00801.x.
本文引用的文献
1
Mixed-function oxidase enzymes in adriamycin-sensitive and resistant sublines of P-388 leukemia.
Chem Biol Interact. 1981 Apr;35(1):119-24. doi: 10.1016/0009-2797(81)90067-3.
2
CHO mutants resistant to colchicine, colcemid or griseofulvin have an altered beta-tubulin.对秋水仙碱、秋水仙酰胺或灰黄霉素具有抗性的CHO突变体具有改变的β-微管蛋白。
Cell. 1980 May;20(1):29-36. doi: 10.1016/0092-8674(80)90231-7.
3
Protective role of the glutathione redox cycle against adriamycin-mediated toxicity in isolated hepatocytes.谷胱甘肽氧化还原循环对阿霉素介导的离体肝细胞毒性的保护作用。
Biochem Pharmacol. 1981 Aug 15;30(16):2299-304. doi: 10.1016/0006-2952(81)90102-7.
4
Increased synthesis of a low molecular weight protein in vincristine-resistant cells.长春新碱耐药细胞中一种低分子量蛋白质的合成增加。
Biochem Biophys Res Commun. 1981 Mar 16;99(1):228-35. doi: 10.1016/0006-291x(81)91736-8.
5
6
Enhancement of vincristine- and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin.维拉帕米增强长春新碱和阿霉素对P388白血病及其长春新碱和阿霉素耐药亚系的细胞毒性作用。
Biochem Pharmacol. 1982 Oct 1;31(19):3138-40. doi: 10.1016/0006-2952(82)90097-1.
7
8
Correlation of double-minute chromosomes with unstable multidrug cross-resistance in uptake mutants of neuroblastoma cells.神经母细胞瘤细胞摄取突变体中双微体染色体与不稳定多药交叉耐药性的相关性
Proc Natl Acad Sci U S A. 1981 Jun;78(6):3654-8. doi: 10.1073/pnas.78.6.3654.
9
Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers.钙内流阻滞剂在体外和体内对长春新碱及阿霉素耐药性的规避作用
Cancer Res. 1983 Jun;43(6):2905-10.
10
Promotion by verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug.维拉帕米对肿瘤细胞系中固有耐药的长春新碱反应性的促进作用。
Cancer Res. 1983 Feb;43(2):808-13.
Zotero 插件